AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX WITH NAB-PACLITAXEL PLUS GEMCITABINE FOR FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER

被引：4
|
作者：
Hollmann, S. [1 ]
Alloul, K. [2 ]
Attard, C. [1 ]
Kavan, P. [3 ]
机构：
[1] Cornerstone Res Grp, Burlington, ON, Canada
[2] Sanofi Canada, Laval, PQ, Canada
[3] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr E 715, Montreal, PQ H3T 1E2, Canada
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu164.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 0018
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX AND NAB-PACLITAXEL (ABARAXANE) PLUS GEMCITABINE FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC CANCER FROM THE US SOCIETAL PERSPECTIVE
    Cheng, W.
    Hay, J. W.
    VALUE IN HEALTH, 2016, 19 (03) : A153 - A153
  • [2] Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china
    Cui, Jiujie
    Zhang, Xiaochen
    Qu, Shuli
    Wang, Liwei
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 691 - 697
  • [3] Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
    Kim, George P.
    Parisi, Monika F.
    Patel, Manish B.
    Pelletier, Corey L.
    Belk, Kathy W.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 559 - 565
  • [4] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [5] Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
    Chen, Jiayuan
    Hua, Qingling
    Wang, Haihong
    Zhang, Dejun
    Zhao, Lei
    Yu, Dandan
    Pi, Guoliang
    Zhang, Tao
    Lin, Zhenyu
    BMC CANCER, 2021, 21 (01)
  • [6] Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
    Jiayuan Chen
    Qingling Hua
    Haihong Wang
    Dejun Zhang
    Lei Zhao
    Dandan Yu
    Guoliang Pi
    Tao Zhang
    Zhenyu Lin
    BMC Cancer, 21
  • [7] Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
    Arciero, Vanessa
    Luo, Jin
    Parmar, Ambica
    Dai, Wei Fang
    Beca, Jaclyn M.
    Raphael, Michael J.
    Isaranuwatchai, Wanrudee
    Habbous, Steven
    Tadrous, Mina
    Earle, Craig C.
    Biagi, Jim J.
    Mittmann, Nicole
    Arias, Jessica
    Gavura, Scott
    Chan, Kelvin K. W.
    JNCI CANCER SPECTRUM, 2022, 6 (04)
  • [8] Comparative effectiveness of FOLFIRINOX (FOL) versus gemcitabine and nab-paclitaxel (GNP) for the first-line treatment of metastatic pancreatic cancer
    Cheng, Wei-Han
    Sadeghi, Sarmad
    Lenz, Heinz-Josef
    Hay, Joel W.
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Jihoon Kang
    Inhwan Hwang
    Changhoon Yoo
    Kyu-pyo Kim
    Jae Ho Jeong
    Heung-Moon Chang
    Sang Soo Lee
    Do Hyun Park
    Tae Jun Song
    Dong Wan Seo
    Sung Koo Lee
    Myung-Hwan Kim
    Seung-Mo Hong
    Sang Hyun Shin
    Dae Wook Hwang
    Ki Byung Song
    Jae Hoon Lee
    Song Cheol Kim
    Baek-Yeol Ryoo
    Investigational New Drugs, 2018, 36 : 732 - 741
  • [10] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Kang, Jihoon
    Hwang, Inhwan
    Yoo, Changhoon
    Kim, Kyu-pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Hong, Seung-Mo
    Shin, Sang Hyun
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 732 - 741
12345